“The 10-year study is an excellent validation of our work toward creating a new durable therapy for eye conditions associated with diabetes,” said Dominik Beck PhD., IRIDEX President and CEO in a press release. “Our goal is to create a paradigm shift in the way physicians treat retinal diseases. Considering the durable clinical benefits, the safety of the procedure and the economic benefits to the healthcare system, leading physicians are beginning to conclude that MicroPulse can be used earlier in the disease progression and can be, at least, incorporated into any treatment regimen – either alone or in conjunction with drug therapy.”
MicroPulse Technology enhances the physician’s ability to precisely aim the laser by using trains of microsecond pulses to more precisely target the treatment and cause less collateral damage to the surrounding area
“MicroPulse laser therapy is an ideal first-line treatment for retinal vascular macular edema because of its unique safety profile,” said Dr. Jefftery Luttrull, ophthalmologist and retinal surgeon with the Ventura County Retina Vitreous Medial Group in California who led the study. “Because of its unique ability to produce the desired therapeutic effect without any measurable inflammation or damage to functional retinal tissue, treatment can be initiated earlier, possibly improving long-term outcomes.”
For more information, please visit www.iridex.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
